Exacerbations among chronic bronchitis patients treated with maintenance medications from a US managed care population: an administrative claims data analysis
Azza AbuDagga,1 Shawn X Sun,2 Hiangkiat Tan,1 Caitlyn T Solem3 1HealthCore Inc, Wilmington, DE, 2Forest Research Institute, Jersey City, NJ, 3Pharmerit North America, Bethesda, MD, USA Purpose: Chronic obstructive pulmonary disease (COPD) exacerbations are the leading cause of hospital admission and...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2013-04-01
|
| Series: | International Journal of COPD |
| Online Access: | http://www.dovepress.com/exacerbations-among-chronic-bronchitis-patients-treated-with-maintenan-a12696 |
| _version_ | 1819042913876705280 |
|---|---|
| author | AbuDagga A Sun SX Tan H Solem CT |
| author_facet | AbuDagga A Sun SX Tan H Solem CT |
| author_sort | AbuDagga A |
| collection | DOAJ |
| description | Azza AbuDagga,1 Shawn X Sun,2 Hiangkiat Tan,1 Caitlyn T Solem3 1HealthCore Inc, Wilmington, DE, 2Forest Research Institute, Jersey City, NJ, 3Pharmerit North America, Bethesda, MD, USA Purpose: Chronic obstructive pulmonary disease (COPD) exacerbations are the leading cause of hospital admission and death among chronic bronchitis (CB) patients. This study estimated annual COPD exacerbation rates, related costs, and their predictors among patients treated for CB. Methods: This was a retrospective study using claims data from the HealthCore Integrated Research Database (HIRDSM). The study sample included CB patients aged ≥ 40 years with at least one inpatient hospitalization or emergency department visit or at least two office visits with CB diagnosis from January 1, 2004 to May 31, 2011, at least two pharmacy fills for COPD medications during the follow-up year, and ≥2 years of continuous enrollment. COPD exacerbations were categorized as severe or moderate. Annual rates, costs, and predictors of exacerbations during follow-up were assessed. Results: A total of 17,382 individuals treated for CB met the selection criteria (50.6% female; mean ± standard deviation age 66.7 ± 11.4 years). During the follow-up year, the mean ± standard deviation number of COPD maintenance medication fills was 7.6 ± 6.3; 42.6% had at least one exacerbation and 69.5% of patients with two or more exacerbations during the 1 year prior to the index date (baseline period) had any exacerbation during the follow-up year. The mean ± standard deviation cost per any exacerbation was $269 ± $748 for moderate and $18,120 ± $31,592 for severe exacerbation. The number of baseline exacerbations was a significant predictor of the number of exacerbations and exacerbation costs during follow-up. Conclusion: Exacerbation rates remained high among CB patients despite treatment with COPD maintenance medications. New treatment strategies, designed to reduce COPD exacerbations and associated costs, should focus on patients with high prior-year exacerbations. Keywords: chronic bronchitis, chronic obstructive pulmonary disease, exacerbations, maintenance medications, managed care |
| first_indexed | 2024-12-21T09:48:27Z |
| format | Article |
| id | doaj.art-c89f0a698c5f4ae89d53c257269da68f |
| institution | Directory Open Access Journal |
| issn | 1176-9106 1178-2005 |
| language | English |
| last_indexed | 2024-12-21T09:48:27Z |
| publishDate | 2013-04-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | International Journal of COPD |
| spelling | doaj.art-c89f0a698c5f4ae89d53c257269da68f2022-12-21T19:08:17ZengDove Medical PressInternational Journal of COPD1176-91061178-20052013-04-012013default175185Exacerbations among chronic bronchitis patients treated with maintenance medications from a US managed care population: an administrative claims data analysisAbuDagga ASun SXTan HSolem CTAzza AbuDagga,1 Shawn X Sun,2 Hiangkiat Tan,1 Caitlyn T Solem3 1HealthCore Inc, Wilmington, DE, 2Forest Research Institute, Jersey City, NJ, 3Pharmerit North America, Bethesda, MD, USA Purpose: Chronic obstructive pulmonary disease (COPD) exacerbations are the leading cause of hospital admission and death among chronic bronchitis (CB) patients. This study estimated annual COPD exacerbation rates, related costs, and their predictors among patients treated for CB. Methods: This was a retrospective study using claims data from the HealthCore Integrated Research Database (HIRDSM). The study sample included CB patients aged ≥ 40 years with at least one inpatient hospitalization or emergency department visit or at least two office visits with CB diagnosis from January 1, 2004 to May 31, 2011, at least two pharmacy fills for COPD medications during the follow-up year, and ≥2 years of continuous enrollment. COPD exacerbations were categorized as severe or moderate. Annual rates, costs, and predictors of exacerbations during follow-up were assessed. Results: A total of 17,382 individuals treated for CB met the selection criteria (50.6% female; mean ± standard deviation age 66.7 ± 11.4 years). During the follow-up year, the mean ± standard deviation number of COPD maintenance medication fills was 7.6 ± 6.3; 42.6% had at least one exacerbation and 69.5% of patients with two or more exacerbations during the 1 year prior to the index date (baseline period) had any exacerbation during the follow-up year. The mean ± standard deviation cost per any exacerbation was $269 ± $748 for moderate and $18,120 ± $31,592 for severe exacerbation. The number of baseline exacerbations was a significant predictor of the number of exacerbations and exacerbation costs during follow-up. Conclusion: Exacerbation rates remained high among CB patients despite treatment with COPD maintenance medications. New treatment strategies, designed to reduce COPD exacerbations and associated costs, should focus on patients with high prior-year exacerbations. Keywords: chronic bronchitis, chronic obstructive pulmonary disease, exacerbations, maintenance medications, managed carehttp://www.dovepress.com/exacerbations-among-chronic-bronchitis-patients-treated-with-maintenan-a12696 |
| spellingShingle | AbuDagga A Sun SX Tan H Solem CT Exacerbations among chronic bronchitis patients treated with maintenance medications from a US managed care population: an administrative claims data analysis International Journal of COPD |
| title | Exacerbations among chronic bronchitis patients treated with maintenance medications from a US managed care population: an administrative claims data analysis |
| title_full | Exacerbations among chronic bronchitis patients treated with maintenance medications from a US managed care population: an administrative claims data analysis |
| title_fullStr | Exacerbations among chronic bronchitis patients treated with maintenance medications from a US managed care population: an administrative claims data analysis |
| title_full_unstemmed | Exacerbations among chronic bronchitis patients treated with maintenance medications from a US managed care population: an administrative claims data analysis |
| title_short | Exacerbations among chronic bronchitis patients treated with maintenance medications from a US managed care population: an administrative claims data analysis |
| title_sort | exacerbations among chronic bronchitis patients treated with maintenance medications from a us managed care population an administrative claims data analysis |
| url | http://www.dovepress.com/exacerbations-among-chronic-bronchitis-patients-treated-with-maintenan-a12696 |
| work_keys_str_mv | AT abudaggaa exacerbationsamongchronicbronchitispatientstreatedwithmaintenancemedicationsfromausmanagedcarepopulationanadministrativeclaimsdataanalysis AT sunsx exacerbationsamongchronicbronchitispatientstreatedwithmaintenancemedicationsfromausmanagedcarepopulationanadministrativeclaimsdataanalysis AT tanh exacerbationsamongchronicbronchitispatientstreatedwithmaintenancemedicationsfromausmanagedcarepopulationanadministrativeclaimsdataanalysis AT solemct exacerbationsamongchronicbronchitispatientstreatedwithmaintenancemedicationsfromausmanagedcarepopulationanadministrativeclaimsdataanalysis |